← All stocks

Amylyx Pharmaceuticals, Inc.

AMLX Net selling

CIK 0001658551 #1444 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$2.94M

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$2.94M

10 of 10 sales

Net

−$2.94M

−$2.94M against sales at will

By person

8 insiders · 12 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Cohen Joshua B

Co-Chief Executive Officer

—

$980.50K (2)

−$980.50K

3,613,123

3.24%

$119.77M

+11.6%

Klee Justin B.

Co-Chief Executive Officer

—

$980.26K (2)

−$980.26K

3,613,056

3.24%

$119.77M

+15.1%

FRATES JAMES M

Chief Financial Officer

—

$349.82K (2)

−$349.82K

273,625

0.2456%

$9.07M

+105.0%

Bedrosian Camille L

Chief Medical Officer

—

$324.87K (2)

−$324.87K

278,064

0.2496%

$9.22M

+79.1%

Mazzariello Gina

Chief Legal Officer

—

$309.51K (2)

−$309.51K

190,838

0.1713%

$6.33M

+26.0%

MILNE GEORGE M JR

Director

—

812,881

0.7295%

$26.95M

−5.3%

Firestone Karen

Director

—

116,900

0.1049%

$3.88M

+112.5%

Zeiher Bernhardt G

Director

—

10,000

0.0090%

$331.49K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Firestone Karen

31 Aug 2026

Director

Exercised, kept

25,000

$5.05

$126.25K

Firestone Karen

31 Aug 2026

Director

Exercised, kept

25,000

$1.76

$44.00K

Show all 12 transactions →

What was left out

Form 4 filings counted 11

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 10

Transactions with no price 0

Shares from compensation/vesting 236,976

History held since 10 Jan 2022